Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

immunocytokine NHS-IL2-LT

A fusion protein consisting of a mouse-human chimeric antibody directed against DNA released by necrotic tumor cells fused to two molecules of a genetically modified human interleukin-2 (IL-2) with potential antineoplastic activity. Upon administration, the antibody moiety of immunocytokine NHS-IL2-LT binds to DNA released by necrotic tumor cells located primarily at the core of necrotic solid tumors, delivering the IL-2 moiety. In turn, the IL-2 moiety of this agent activates the immune system to mount a cytotoxic T-lymphocyte response against nearby tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:interleukin-2 fusion protein MSB0010445
Foreign brand name:Selectikine
Abbreviation:Ch.14.18-IL2
Code name:EMD 521873
MSB0010445
NHS-IL2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search